SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 67 of 87
Word Count: 1481
Character Count: 9597

Document Content:

the recent market prices of, and the demand for, publicly traded shares of generally comparable companies, as well as the recent market price of our common stock. Listing intend to apply to have our common stock listed on Nasdaq under the symbol “BVXX”. In order to meet one of the requirements for listing our common stock on Nasdaq, the underwriters have undertaken to sell lots of 100 or more shares to a minimum of 300 beneficial holders. Stabilization connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids, and purchases to cover positions created by short sales. ● Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while this offering is in progress.

●	Over-allotment
transactions involve sales by the underwriters of securities in excess of the number of securities
the underwriters are obligated to purchase. This creates a syndicate short position which
may be either a covered short position or a naked short position. In a covered short position,
the number of securities over-allotted by the underwriters is not greater than the number
of securities that they may purchase in the over-allotment option. In a naked short position,
the number of securities involved is greater than the number of securities in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment
option and/or purchasing securities in the open market.

●	Syndicate
covering transactions involves purchases of securities in the open market after the distribution
has been completed in order to cover syndicate short positions. In determining the source
of securities to close out the short position, the underwriters will consider, among other
things, the price of securities available for purchase in the open market as compared with
the price at which they may purchase securities through exercise of the over-allotment option.
If the underwriters sell more securities than could be covered by exercise of the over-allotment
option and, therefore, have a naked short position, the position can be closed out only by
buying securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that after pricing there could be downward pressure on
the price of the securities in the open market that could adversely affect investors who
purchase in this offering.

●	Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when
the securities originally sold by that syndicate member are purchased in stabilizing or syndicate
covering transactions to cover syndicate short positions.

These
stabilizing transactions, over-allotment transactions, syndicate covering transactions, and penalty bids may have the effect of raising
or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result,
the price of our securities in the open market may be higher than it would otherwise be in the absence of these transactions. Neither
we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the
price of our securities. These transactions may be affected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and,
if commenced, may be discontinued at any time.

Passive
Market Making

connection with this offering, underwriters, and selling group members may engage in passive market making transactions in our securities
on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.

Other
Relationships

The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging,
market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective
affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships
with us, for which they received or will receive customary fees and expenses.

Offer
Restrictions Outside the United States

Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.

Selling
Restrictions

Australia

This
prospectus:

●	does
not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations
Act 2001 (Cth), or the Corporations Act;

●	has
not been, and will not be, lodged with the Australian Securities and Investments Commission,
or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport
to include the information required of a disclosure document for the purposes of the Corporations
Act; and

●	may
only be provided in Australia to select investors who are able to demonstrate that they fall
within one or more of the categories of investors, available under section 708 of the Corporations
Act, or Exempt Investors.

The
securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy
the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any
securities may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations
Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities,
you represent and warrant to us that you are an Exempt Investor.

any offer of securities under this prospectus will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act,
the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure
to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the securities you undertake
to us that you will not, for a period of 12 months from the date of issue of the securities, offer, transfer, assign or otherwise alienate
those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of
the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.

Canada

The
securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients,
as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws.

Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars
of these rights or consult with a legal advisor.

Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.

European
Economic Area